Drugs / Sulfonylurea
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02111096 Background | Apr 2014 → Sep 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT03066830 Comparator | Feb 2017 → Apr 2019 | type 2 diabetes mellitus | Lexicon Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT01972724 Background | Dec 2013 → Oct 2016 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-12-01 | Eli Lilly and Company | New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea lilly.com ↗ |
| 2013-06-22 | Eli Lilly and Company | Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes lilly.com ↗ |
| 2011-06-24 | Eli Lilly and Company | Two-Year Data Comparing Cardiovascular Events with Linagliptin and the Sulfonylurea, Glimepiride, Presented as Late-Breaking Poster at ADA lilly.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulfonylurea | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111096 ↗ |
| Route | Oral | “Administered orally” NCT02111096 ↗ |